Search

Savara Inc

Geschlossen

BrancheGesundheitswesen

5.42 0.93

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

5.28

Max

5.42

Schlüsselkennzahlen

By Trading Economics

Einkommen

-5M

-37M

Angestellte

70

EBITDA

-3.8M

-37M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+108.01% upside

Dividenden

By Acuity

Nächstes Ergebnis

10. Nov. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

125M

1.2B

Vorheriger Eröffnungskurs

4.49

Vorheriger Schlusskurs

5.42

Nachrichtenstimmung

By Acuity

79%

21%

318 / 340 Ranking in Healthcare

Savara Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

17. Aug. 2026, 19:46 UTC

Savara Inc is trading lower today, retracing from earlier gains and near the lower end of its one-month range. No specific news was identified.

14. Aug. 2026, 19:44 UTC

Savara Inc shares are higher today amid increased trading volume. No specific company news was identified to explain the price movement.

13. Aug. 2026, 20:02 UTC

Savara Inc shares are lower today, continuing a decline since Wednesday. The stock saw high trading volume amid no specific news.

12. Aug. 2026, 19:56 UTC

News

Savara Inc. shares are higher following Citizens' reaffirmation of its Outperform rating and $10 price target ahead of the MOLBREEVI PDUFA date.

11. Aug. 2026, 19:11 UTC

Savara Inc shares are lower today amid unusually high market volume. No specific news was identified to explain the decline.

10. Aug. 2026, 23:01 UTC

Savara Inc shares are lower in after-market trading, showing notable volatility without any specific news to explain the decline.

7. Aug. 2026, 19:36 UTC

Savara Inc is trading higher, benefiting from broader market gains following a weaker-than-expected jobs report that may delay Federal Reserve interest rate hikes.

6. Aug. 2026, 20:06 UTC

Savara Inc shares are higher today, recovering from earlier declines and trading above their 20-day moving average. No specific news was identified for the move.

5. Aug. 2026, 19:36 UTC

News

Savara Inc. shares are higher as the company advances its Biologics License Application for molgramostim, with a key PDUFA date approaching.

4. Aug. 2026, 23:01 UTC

Savara Inc shares are trading higher in after-market hours, showing significant volatility with no specific news identified to explain the price movement.

3. Aug. 2026, 20:06 UTC

Savara Inc is declining today, diverging from recent higher closes. Broader market indices, including the S&P 500 and Nasdaq 100, are gaining.

31. Juli 2026, 20:06 UTC

Event

Savara Inc shares are lower despite the European Patent Office granting a patent for MOLBREEVI, effective through March 2041. The stock remains near its one-month low.

30. Juli 2026, 20:09 UTC

Event

Savara Inc shares rise after the European Patent Office grants a patent for MOLBREEVI, providing protection until March 2041.

29. Juli 2026, 19:47 UTC

Savara Inc's shares are lower, marking five consecutive sessions of decline. Broader market performance is mixed as traders await the Federal Reserve's interest rate decision.

28. Juli 2026, 19:16 UTC

Savara Inc. shares are lower today amid ongoing price weakness. Broader markets like the FTSE 100 and DAX are showing resilience despite this decline.

27. Juli 2026, 14:02 UTC

Savara Inc shares are higher during Monday's session, reaching their peak at 9:30 AM ET. No specific news was identified to explain the movement.

24. Juli 2026, 20:02 UTC

Savara Inc shares are lower today, continuing a decline since Thursday amid high market volume. Broader market sentiment is affected by recent oil price volatility.

21. Juli 2026, 17:41 UTC

Savara Inc. shares are advancing today amid strong trading volume. The broader market is also positive, led by gains in technology stocks.

20. Juli 2026, 20:06 UTC

Savara Inc shares are higher, continuing their advance from Friday's close. Broader market sentiment remains mixed amid ongoing geopolitical concerns.

Peer-Vergleich

Kursveränderung

Savara Inc Prognose

Kursziel

By TipRanks

108.01% Vorteil

12-Monats-Prognose

Durchschnitt 11.17 USD  108.01%

Hoch 16 USD

Tief 9 USD

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Savara Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

6 ratings

6

Buy

0

Halten

0

Sell

Stimmung

By Acuity

318 / 340 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Savara Inc

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.
help-icon Live chat